Replies to post #56621 on Biotech Values

[ThomasS]

MNTA: I should point out that the profit-sharing arrangement for M356 Copaxone is favorable for MNTA in a manner which probably won't be repeated for the other 2 compounds M178/249.
M356 was a MNTA compound before the Sandoz collaboration; hence, the future terms may well be quite less, although substantial, depending on the drug.

[rkrw]

178 and 249 came from Sandoz originally. I'd guess the royalties are single digit, not 50/50, but who knows since they wont say.

On fragmin, I guess you missed my point in that it will never be developed. Not commercially attractive.

this is from the mnta 10K:

<<<The M-Dalteparin program has been reprioritized in light of other more commercially attractive opportunities.>>>